Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 31 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 31 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1
30(96.8%)
N/A
1(3.2%)
31Total
Phase 1(30)
N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (31)

Showing 20 of 31 trials
NCT01884909Phase 1Completed

Bioequivalence Study of Metoprolol Succinate Extended Release Tablets 200 mg Under Fed Conditions

Role: lead

NCT01884857Phase 1Completed

Bioequivalence Study of Metoprolol Succinate Extended Release Tablets 50 mg

Role: lead

NCT01884896Phase 1Completed

Bioequivalence Study of Metoprolol Succinate Extended Release Tablets 200 mg Under Fasting Conditions

Role: lead

NCT01831661Phase 1Completed

Bioequivalence Study of Metformin Hydrochloride Extended-Release Tablets USP 750 mg Under Fasting Condition

Role: lead

NCT01831700Phase 1Completed

Bioequivalence Study of Lisinopril and Hydrochlorothiazide Tablets (20+25) mg Under Fasting Conditions

Role: lead

NCT01831687Phase 1Completed

Bioequivalence Study of Etodolac Extended Release Tablets USP 600mg Under Fed Condition

Role: lead

NCT01831674Phase 1Completed

Bioequivalence Study of Metformin Hydrochloride Extended-Release Tablets USP 750 mg Under Fed Condition

Role: lead

NCT01827878Phase 1Completed

Bioequivalence Study of Lisinopril and Hydrochlorothiazide Tablets (20+25) mg Under Fed Conditions

Role: lead

NCT01827865Phase 1Completed

Bioequivalence Study of Etodolac Extended Release Tablets USP 600mg Under Fasting Condition

Role: lead

NCT01749228Phase 1Completed

Bioequivalence Study of Etodolac Capsules USP 300 mg Under Fed Condition

Role: lead

NCT01746719Phase 1Completed

Bioequivalence Study of Etodolac Capsules USP 300 mg Under Fasting Condition

Role: lead

NCT01744873Phase 1Completed

Bioequivalence Study of Bisoprolol Fumarate Tablet 10 mg Under Fed Condition

Role: lead

NCT01741623Phase 1Completed

Bioequivalence Study of Bisoprolol Fumarate Tablet 10 mg Under Fasting Condition

Role: lead

NCT01567501Phase 1Completed

Bioequivalence Study of Levocetirizine Dihydrochloride Tablets 5 mg Under Fed Condition

Role: lead

NCT01735318Phase 1Completed

Bioequivalence Study of Lisinopril Tablets 40 mg Under Fasting Condition

Role: lead

NCT01557439Phase 1Completed

Bioequivalence Study of Levocetirizine Dihydrochloride Tablets 5 mg Under Fasting Condition

Role: lead

NCT01735370Phase 1Completed

Bioequivalence Study of Etodolac Tablet USP 500 mg Under Fasting Condition

Role: lead

NCT01735344Phase 1Completed

Bioequivalence Study of Lisinopril Tablets 40 mg Under Fed Condition

Role: lead

NCT01735383Phase 1Completed

Bioequivalence Study of Etodolac Tablet USP 500 mg Under Fed Condition

Role: lead

NCT01722201Phase 1Completed

Bioequivalence Study of Risperidone Tablet 1 mg Under Fasting Condition

Role: lead